ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

10:30AM-12:30PM: Abstract Number: 0229

Leveraging the Electronic Medical Record to Improve the Rate of Discrete Data Collection in a Pediatric Rheumatology Clinic

(0210–0232) Measures & Measurement of Healthcare Quality Poster I

10:30AM-12:30PM: Abstract Number: 0494

LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates

(0470–0505) Rheumatoid Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0131

Libman-Sacks Endocarditis in APS: A Case-Control Study of Clinical and Serologic Features

(0115–0144) Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0371

Lifestyle Coaching in Psoriatic Arthritis: Pilot Findings from an Online eCoaching Program

(0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0437

Lipid Screening in Rheumatoid Arthritis: A Retrospective Cohort Study Highlighting Gaps in Cardiovascular Risk Prevention

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: PP08

Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient

(PP01-PP08) Patient Perspectives Poster

10:30AM-12:30PM: Abstract Number: 0582

Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0420

Long-term efficacy of intra-articular triamcinolone hexacetonide injections in juvenile idiopathic arthritis patients starting tumor necrosis factor inhibitor therapy: 48 weeks results from a randomized, open-label, blinded-assessor multicenter phase 4 trial – the MyJIA trial

(0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0401

Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry

(0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0023

Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors

(0019–0048) Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 0297

Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis

(0280–0305) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0597

Low 25-hydroxyvitamin D Levels are Associated with Higher Mortality and More Cardiovascular Events in Systemic Lupus Erythematosus

(0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0444

Low Disease Activity: Good Enough?

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0656

Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial

(0641–0670) Systemic Lupus Erythematosus – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0540

Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease

(0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].